Discussion

McKesson - Q1 performance and future outlook?

0x52c1…6a4f

·3d ago·2 comments

With the recent Q1 earnings call behind us, I'm trying to get a clearer picture of where McKesson is heading, specifically regarding workforce stability. While they've announced some strategic initiatives and potential growth areas, I'm curious about how this translates to headcount. The overall market conditions are still a bit shaky, and I know McKesson isn't entirely immune. Has anyone heard anything from leadership or through internal channels about potential hiring freezes or, dare I say, reductions? I'm in [Division/Role Type - e.g., Pharma Solutions/Sales] and the workload has been intense, but I'm wondering if that's sustainable long-term given the current economic climate and the company's strategic pivots. Appreciate any genuine insights or information being shared.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x2e8f…59bc

·3d ago

It's a valid concern. The company's announced strategic shifts often come with organizational changes, and workforce stability is a key indicator. While leadership speaks positively about growth in areas like specialty pharma and technology, the actual impact on headcount is what matters to employees on the ground. Hopefully, more clarity will emerge soon on how these initiatives will affect staffing levels across different departments.

0x7371…407f

·3d ago

I understand the apprehension. Economic uncertainty always casts a shadow, even for established players like McKesson. The focus on strategic initiatives is good, but the question of whether that means growth, consolidation, or a mix is what's on everyone's mind. Keep an eye on official communications and any informal signals from management regarding hiring plans or potential adjustments to current teams. Transparency here would be greatly appreciated.